Improvement in disability is demonstrated as measured by Modified Rankin Score as compared to the previous review assessment Refer to the current product Dose Induction Dose– Up to 2g/kg in 2 to 5 divided doses Induction and maintenance doses have been information sheet for further developed and agreed by Specialist Working Review after 1 month, if improvement demonstrated but information. Group consensus. symptoms persist, further courses can be considered every The aim should be to use the three months. lowest dose possible that Maintenance Dose 1.5 g/kg, 4 to 6 weekly –1- achieves the appropriate clinical outcome for each patient. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information on dose, administration and contraindications. References (most recent update: February 2016) Chang K, Frankovich J, Cooperstock M, Cunningham M, Latimer M, Murphy T, et al (2015) Clinical Evaluation of youth with pediatric Acute-onset neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference. Journal of Child and Adolescent Psychopharmacology, Kovacevic M, Grant P and Swedo SE (2015) Use of Intravenous Immunoglobulin in the treatment of 12 Youths with pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections. 25:65-69. Journal of Child and Adolescent Psychopharmacology,
Improvement in disability is demonstrated as measured by Modified Rankin Score as compared to the previous review assessment Dose Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Induction Dose– Up to 2g/kg in 2 to 5 divided doses Review after 1 month, if improvement demonstrated but symptoms persist, further courses can be considered every three months. Maintenance Dose –1- 1.5 g/kg, 4 to 6 weekly The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information on dose, administration and contraindications. Induction and maintenance doses have been developed and agreed by Specialist Working Group consensus. References (most recent update: February 2016) Chang K, Frankovich J, Cooperstock M, Cunningham M, Latimer M, Murphy T, et al (2015) Clinical Evaluation of youth with pediatric Acute-onset neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference. Journal of Child and Adolescent Psychopharmacology, Kovacevic M, Grant P and Swedo SE (2015) Use of Intravenous Immunoglobulin in the treatment of 12 Youths with pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections. Journal of Child and Adolescent Psychopharmacology, 25:65-69.
Paediatric-autoimmune-neuropsychiatric-disorder-associated-with-streptococcal-infection-%28PANDAS%292017.docx